Tatva Chintan Pharma Chem IPO -- Should you subscribe? Here’s what analysts are saying
- The Gujarat-based speciality chemical company, Tatva Chintan Pharma Chem IPO, opens on Friday and closes on July 20.
- The IPO has a price band of ₹1,073-1,083 while it is looking to raise ₹500 crore through the public issue.
- Most analysts have suggested subscribing to the IPO for the long term on strong growth opportunities in global markets.
Tatva Chintan Pharma Chem has opened its initial public offering (IPO) bidding window for all investors. This is the second speciality chemical industry IPO to get launched in July after Clean Science and Technology.
View all Offers
View all Offers
- 26% OFF
Samsung Galaxy M52 5G (ICY Blue, 6GB RAM, 128GB Storage) Latest Snapdragon 778G 5G | sAMOLED 120Hz Display₹ 25999₹ 34999Buy On
- 10% OFF
Redmi Note 10 Pro (Dark Night, 6GB RAM, 128GB Storage) -120hz Super Amoled Display|64MPwith 5mp Super Tele-Macro₹ 17999₹ 19999Buy On
- 48% OFF
Samsung Galaxy Note 20 (Mystic Bronze, 8GB RAM, 256GB Storage) with No Cost EMI/Additional Exchange Offers₹ 44999₹ 86000Buy On
OnePlus Nord CE 5G (Charcoal Ink, 8GB RAM, 128GB Storage)₹ 24999₹ 24999Buy On
- 8% OFF
OnePlus 9R 5G (Lake Blue, 8GB RAM, 128GB Storage)₹ 36999₹ 39999Buy On
The IPO will include ₹225 crore of fresh equity shares by the company and ₹275 crore of offer for sale (OFS) by promoters and shareholders.
The company manufactures a range of products in specialty chemicals category and serves industries like automotive, petroleum, pharmaceutical, agro chemicals, paints and coatings, dyes and pigments, personal care and flavour and fragrances industries.
AdvertisementHere are the important details to note:
|Price band||₹1,073 - ₹1,083|
|IPO open date||July 16|
|IPO close date||July 20|
|Allotment date||July 26|
|Initiation of refunds||July 27|
|Credit of shares to demat account||July 28|
|IPO listing date||July 29|
Most analysts have recommended subscribing to the IPO on attractive opportunities in global markets.
|Investmentz||Subscribe for long term|
“The company earns 30% of revenue from pharmaceutical and agrochemical intermediates and other specialty chemicals, which are basically export orders shifted from China to India. With its superior product mix, established brand name, forward integration, strong relationships with multinationals, and adding capacities, we believe Tatva Chintan is likely to deliver healthy financial performance,” said a report by stock broking platform Investmentz. Hence it recommends subscribing to the issue from a long-term perspective.
In an interview with Business Insider ahead of the IPO, Mahesh Tanna, chief financial officer (CFO) at Tatva Chintan Pharma Chem highlighted that pharmaceutical and agrochemical intermediates and other specialty chemicals (PASC) segment is getting almost 30% of revenues from countries that have been looking for alternatives other than Chinese products.
The PASC category includes specialty chemicals which are used as intermediates, disinfectants, catalysts and solvents.
Many countries have started following China Plus One policy, which is the business strategy to avoid investing only in China and diversify business into other countries.
“India’s specialty chemical companies are gaining favour with global multinationals because of the geopolitical shift after the outbreak of covid-19 as the world looks to reduce dependence on China. Currently, China accounts for approximately 15-17% of the world’s exportable specialty chemicals, whereas India accounts for just 1-2%, indicating that the country has a large scope of improvement and widespread opportunity. It is anticipated that specialty chemicals will be the next great export pillar for India,” said Sharekhan in a report.
The overall global specialty chemical market stood at approximately $800 billion in 2019, and is expected to grow by 5-6% in the next five years, added the report.
Analysts at Reliance Securities believe the company has a robust earnings growth potential in the long-run led by strong market share, capacity expansion and long-standing relationship with the key customers.
“Moreover, the high valuations of the company’s issue price are justified given the high growth potential, dominant player, exposure to green energy, and strong balance sheet,” said a research report by Ventura Securities.
SEE ALSO: Tatva Chintan Pharma Chem IPO: Here’s how to apply via banks and apps like Zerodha, Upstox
Infosys has a new headache — India’s unicorn boom
Popular on BI
- Nykaa’s IPO to open tomorrow — check last date, listing date and more
- Best plastic stool for home in India
- Best wooden stool for living room in India
- PolicyBazaar’s parent to open its ₹5,700 crore IPO on November 1
- Best coffee and tea mugs for your office or home